Brief: Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
16/07/2024 13:26
July 16 (Reuters) - Celldex Therapeutics Inc CLDX.O :
* CELLDEX THERAPEUTICS INITIATES GLOBAL PHASE 3 PROGRAM FOR
BARZOLVOLIMAB IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA
* CELLDEX THERAPEUTICS INC -EMBARQ-CSU1 AND EMBARQ-CSU 2
WILL
ENROLL MORE THAN 1800 PATIENTS SUFFERING FROM CSU
Source text for Eikon: ID:nGNX90KkLJ
Further company coverage: CLDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celldex Therapeutics
See all newsUS RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Celldex shares slip as safety concerns cloud skin drug trial win (updated)
Celldex falls after two probable anaphylaxis cases in trials
Celldex's skin disease drug meets goals in two late-stage trials